70 related articles for article (PubMed ID: 11103099)
1. The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women.
Halpner AD; Kellermann G; Ahlgrimm MJ; Arndt CL; Shaikh NA; Hargrave JJ; Tallas PG
J Womens Health Gend Based Med; 2000 Nov; 9(9):995-8. PubMed ID: 11103099
[TBL] [Abstract][Full Text] [Related]
2. Markers of bone turnover in postmenopausal women receiving hormone replacement therapy.
Hamwi A; Ganem AH; Grebe C; Kerschan-Schindl K; Preisinger E; Boschitsch E; Bieglmayer C
Clin Chem Lab Med; 2001 May; 39(5):414-7. PubMed ID: 11434391
[TBL] [Abstract][Full Text] [Related]
3. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D supplementation in postmenopausal black women.
Kyriakidou-Himonas M; Aloia JF; Yeh JK
J Clin Endocrinol Metab; 1999 Nov; 84(11):3988-90. PubMed ID: 10566638
[TBL] [Abstract][Full Text] [Related]
5. Effect of isoflavones on lipids and bone turnover markers in menopausal women.
Schult TM; Ensrud KE; Blackwell T; Ettinger B; Wallace R; Tice JA
Maturitas; 2004 Jul; 48(3):209-18. PubMed ID: 15207886
[TBL] [Abstract][Full Text] [Related]
6. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
7. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial.
Di Daniele N; Carbonelli MG; Candeloro N; Iacopino L; De Lorenzo A; Andreoli A
Pharmacol Res; 2004 Dec; 50(6):637-41. PubMed ID: 15501704
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss.
Ushiroyama T; Okamura S; Ikeda A; Ueki M
Int J Gynaecol Obstet; 1995 Mar; 48(3):283-8. PubMed ID: 7781871
[TBL] [Abstract][Full Text] [Related]
9. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
10. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
11. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women.
Kritz-Silverstein D; Goodman-Gruen DL
J Womens Health Gend Based Med; 2002; 11(1):69-78. PubMed ID: 11860727
[TBL] [Abstract][Full Text] [Related]
12. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency.
Kamel S; Brazier M; Rogez JC; Vincent O; Maamer M; Desmet G; Sebert JL
J Clin Endocrinol Metab; 1996 Oct; 81(10):3717-21. PubMed ID: 8855828
[TBL] [Abstract][Full Text] [Related]
13. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
14. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
Kovács AB
Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
[TBL] [Abstract][Full Text] [Related]
16. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption.
Bonde M; Fledelius C; Qvist P; Christiansen C
Clin Chem; 1996 Oct; 42(10):1639-44. PubMed ID: 8855148
[TBL] [Abstract][Full Text] [Related]
17. Effect of yogurt on a urinary marker of bone resorption in postmenopausal women.
Heaney RP; Rafferty K; Dowell MS
J Am Diet Assoc; 2002 Nov; 102(11):1672-4. PubMed ID: 12449294
[TBL] [Abstract][Full Text] [Related]
18. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
19. Potential role of the antioxidant N-acetylcysteine in slowing bone resorption in early post-menopausal women: a pilot study.
Sanders KM; Kotowicz MA; Nicholson GC
Transl Res; 2007 Oct; 150(4):215. PubMed ID: 17900508
[No Abstract] [Full Text] [Related]
20. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA.
Fledelius C; Kolding I; Qvist P; Bonde M; Hassager C; Reginster JY; Hejgaard J; Frøokiaer H; Christiansen C
Scand J Clin Lab Invest; 1997 Feb; 57(1):73-83. PubMed ID: 9127460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
